10x Genomics, Inc.
10x Genomics, Inc. (TXG) Financial Performance & Income Statement Overview
Explore the financials of 10x Genomics, Inc. (TXG), including yearly and quarterly data on income, cash flow, and balance sheets.
10x Genomics, Inc. (TXG) Income Statement & Financial Overview
Access detailed annual and quarterly income data for 10x Genomics, Inc. TXG financial performance.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $154.88M | $165.02M | $151.65M | $153.10M |
| Cost of Revenue | $49.44M | $54.07M | $45.26M | $46.21M |
| Gross Profit | $105.44M | $110.95M | $106.39M | $106.90M |
| Gross Profit Ratio | $0.68 | $0.67 | $0.70 | $0.70 |
| R&D Expenses | $64.25M | $66.97M | $66.17M | $62.92M |
| SG&A Expenses | $89.73M | $93.83M | $81.70M | $83.04M |
| Operating Expenses | $153.97M | $160.79M | $147.88M | $148.63M |
| Total Costs & Expenses | $203.41M | $221.99M | $193.14M | $194.84M |
| Interest Income | $3.69M | $4.03M | $4.97M | $4.71M |
| Interest Expense | $0.00 | $0.00 | $2000.00 | $1000.00 |
| Depreciation & Amortization | $0.00 | $10.56M | $10.75M | $10.90M |
| EBITDA | -$39.33M | -$37.82M | -$23.69M | -$26.18M |
| EBITDA Ratio | -$0.25 | -$0.23 | -$0.16 | -$0.17 |
| Operating Income | -$39.33M | -$49.84M | -$41.48M | -$41.74M |
| Operating Income Ratio | -$0.25 | -$0.30 | -$0.27 | -$0.27 |
| Other Income/Expenses (Net) | $5.82M | $1.46M | $7.05M | $4.66M |
| Income Before Tax | -$33.51M | -$48.38M | -$34.44M | -$37.08M |
| Income Before Tax Ratio | -$0.22 | -$0.29 | -$0.23 | -$0.24 |
| Income Tax Expense | $852000.00 | $648000.00 | $1.31M | $818000.00 |
| Net Income | -$34.36M | -$49.03M | -$35.75M | -$37.90M |
| Net Income Ratio | -$0.22 | -$0.30 | -$0.24 | -$0.25 |
| EPS | -$0.28 | -$0.41 | -$0.30 | -$0.32 |
| Diluted EPS | -$0.28 | -$0.41 | -$0.30 | -$0.32 |
| Weighted Avg Shares Outstanding | $122.61M | $121.60M | $120.73M | $120.07M |
| Weighted Avg Shares Outstanding (Diluted) | $122.61M | $121.60M | $120.73M | $120.07M |
The company's financials show resilient growth, with revenue advancing from $153.10M in Q2 2024 to $154.88M in Q1 2025. Gross profit remained healthy with margins at 68% in Q1 2025 compared to 70% in Q2 2024. Operating income hit -$39.33M last quarter, sustaining a consistent -25% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$39.33M. Net income rose to -$34.36M, while earnings per share reached -$0.28. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan